Yang Li, Wu Yufeng, Tang Hong, Zhao Jiuzhou, Zhao Dongdong, Yang Sen, Wang Qiming
Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
Department of Molecular Pathology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
Onco Targets Ther. 2018 Apr 5;11:1921-1927. doi: 10.2147/OTT.S155033. eCollection 2018.
The purpose of this article is to explore the targeted treatment of malignant myofibroblastoma and evaluate the role of neoplasm metabolite markers in the evaluation of efficacy after targeted therapy.
This report described a case of myofibroblastic sarcoma with rare mutation of in a 58-year-old man prescribed with crizotinib, to evaluate its curative effect by positron emission tomography coupled with computed tomography (PET-CT). After the progressive disease in the brain, bevacizumab combined with crizotinib was administered. The Response Evaluation Criteria in Solid Tumors (RECIST), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were used to assess the efficacy. The efficacy was assessed by comparing changes in MTV and TLG.
After the treatment of crizotinib, the tumor volume was decreased. However, bevacizumab combined with crizotinib had not improved the prognosis. The change of MTV and TLG was consistent with the efficacy. The increase of MTV and TLG is an early indicator of the poor prognosis of patients.
The treatment of the crizotinib patient with the mutation of was effective. The values of MTV and TLG reflected the prognosis earlier than RECIST.
本文旨在探讨恶性肌成纤维细胞瘤的靶向治疗，并评估肿瘤代谢标志物在靶向治疗后疗效评估中的作用。
本报告描述了一例58岁男性肌成纤维细胞肉瘤患者，该患者存在罕见突变，接受克唑替尼治疗，通过正电子发射断层扫描结合计算机断层扫描（PET-CT）评估其疗效。脑转移进展后，给予贝伐单抗联合克唑替尼治疗。采用实体瘤疗效评价标准（RECIST）、代谢肿瘤体积（MTV）和总病灶糖酵解（TLG）评估疗效。通过比较MTV和TLG的变化来评估疗效。
克唑替尼治疗后，肿瘤体积缩小。然而，贝伐单抗联合克唑替尼并未改善预后。MTV和TLG的变化与疗效一致。MTV和TLG升高是患者预后不良的早期指标。
对存在该突变的患者使用克唑替尼治疗有效。MTV和TLG值比RECIST更早反映预后。
